Skip to main
PRAX

PRAX Stock Forecast & Price Target

PRAX Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 77%
Buy 15%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Praxis Precision Medicine's stock outlook appears positive due to significant advancements in the clinical efficacy of its product candidates, particularly vormatrigine, which demonstrated a 100% reduction in seizure frequency among patients, up from 56% in previous updates. The increased percentage of patients achieving 100% focal seizure reduction, now at over 33%, enhances its competitive position against existing treatments, suggesting potential for improved market share and persistence in usage. Furthermore, relutrigine's strong performance in demonstrating superior seizure reduction in specific genetic disorders indicates promising clinical data that could further bolster the company’s growth trajectory in the biopharmaceutical market.

Bears say

Praxis Precision Medicines Inc faces significant risks that may adversely impact its stock performance, including potential developmental failures in its key clinical-stage programs, vormatrigine and relutrigine, as well as the possibility of lower-than-expected sales from these candidates. Additionally, the company is susceptible to increased competitive pressure within the central nervous system disorder market, which could hinder its market share and profitability. Furthermore, reliance on third-party suppliers introduces manufacturing risks that could lead to delays in clinical trial timelines, compounding the overall uncertainty regarding the successful commercialization of its product candidates.

PRAX has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 77% of analysts recommend a Strong Buy, 15% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Praxis Precision Medicines and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Praxis Precision Medicines (PRAX) Forecast

Analysts have given PRAX a Strong Buy based on their latest research and market trends.

According to 13 analysts, PRAX has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $396.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $396.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Praxis Precision Medicines (PRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.